Omarigliptin

Omarigliptin is a potent, long-acting oral antidiabetic drug of the DPP-4 inhibitor class used for once-weekly treatment of type 2 diabetes and currently under development by Merck & [Co.] It inhibits DPP-4 to increase incretin levels, which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying and decreases blood glucose levels.

History

Marizev 25 mg and 12.5 mg tablets were approved by Japan's Pharmaceuticals and [Medical Devices Agency] on 28th Sept 2015. Japan was the first country to have approved omarigliptin. However Merck has announced that the company will not submit marketing application in the US and Europe.